Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic
Göster/ Aç
Erişim
info:eu-repo/semantics/openAccessTarih
2021Yazar
Kalyoncu, UmutPehlivan, Yavuz
Akar, Servet
Kaşifoğlu, Timuçin
Kimyon, G.
Karadağ, Ö.
Kiraz, Sedat
Mercan, Rıdvan
Üst veri
Tüm öğe kaydını gösterÖzet
Background/aim: To evaluate treatment adherence and predictors of drug discontinuation among patients with inflammatory arthritis receiving bDMARDs within the first 100 days after the announcement of the COVID-19 pandemic. Materials and methods: A total of 1871 patients recorded in TReasure registry for whom advanced therapy was prescribed for rheumatoid arthritis (RA) or spondyloarthritis (SpA) within the 3 months (6–9 months for rituximab) before the declaration of COVID-19 pandemic were evaluated, and 1394 (74.5%) responded to the phone survey. Patients’ data regarding demographic, clinical characteristics and disease activity before the pandemic were recorded. The patients were inquired about the diagnosis of COVID-19, the rate of continuation on bDMARDs, the reasons for treatment discontinuation, if any, and the current general disease activity (visual analog scale, [VAS]). Results: A total of 1394 patients (493 RA [47.3% on anti-TNF] patients and 901 SpA [90.0% on anti-TNF] patients) were included in the study. Overall, 2.8% of the patients had symptoms suggesting COVID-19, and 2 (0.15%) patients had PCR-confirmed COVID-19. Overall, 18.1% of all patients (13.8% of the RA and 20.5% of the SpA; p = 0.003) discontinued their bDMARDs. In the SpA group, the patients who discontinued bDMARDs were younger (40 [21–73] vs. 44 years [20–79]; p = 0.005) and had higher general disease activity; however, no difference was relevant for RA patients. Conclusion: Although the COVID-19 was quite uncommon in the first 100 days of the pandemic, nearly one-fifth of the patients discontinued bDMARDs within this period. The long-term effects of the pandemic should be monitored. © TÜBİTAK.
Cilt
51Sayı
4Koleksiyonlar
İlgili Öğeler
Başlık, yazar, küratör ve konuya göre gösterilen ilgili öğeler.
-
Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: Cross-sectional data from the psoriatic arthritis-international database
Bilgin, E.; Aydın, S.Z.; Tinazzi, I.; Bayındır, Ö.; Kimyon, G.; Özişler, C.; Kalyoncu, Umut; Mercan, Rıdvan (Clinical and Experimental Rheumatology S.A.S., 2021)Objective To explore the impact of early versus late-onset psoriasis (PsO) on the disease characteristics of psoriatic arthritis (PsA) in a large-multicentre cohort. Methods The data from a multicentre psoriatic arthritis ... -
Methodology of a new inflammatory arthritis registry: TReasure
Kalyoncu, Umut; Tascilar, Etem Koray; Ertenli, Ali İhsan; Dalkılıç, Hüseyin Ediz; Bes, Cemal; Küçükşahin, Orhan; Kiraz, Sedat; Mercan, Rıdvan (Tubitak Scientific & Technical Research Council Turkey, 2018)Background/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritis patients. This article reviews the methodology and objectives of the TReasure registry ... -
Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all?
İlgen, Ufuk; Karadağ, Ömer; Emmungil, Hakan; Küçükşahin, Orhan; Koca, Süleyman Serdar; Erden, Abdulsamet; Kalyoncu, Umut; Mercan, Rıdvan (Springer Heidelberg, 2022)This study aimed to compare Tuberculin Skin Test (TST) and QuantiFERON (R)-TB Gold In-Tube (QFT-GIT) test in rheumatoid arthritis (RA) and spondyloarthritis (SpA) patients scheduled for biological and targeted synthetic ...